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Abstract 
 
The second scientific workshop of the European Crohn’s and Colitis Organization (ECCO) 
focused on the relevance of intestinal healing for the disease course of inflammatory bowel 
disease (IBD). The objective was to better understand basic mechanisms, markers for disease 
prediction, detection and monitoring of intestinal healing, impact of intestinal healing on the 
disease course of IBD as well as therapeutic strategies. The results of this workshop are 
presented in four separate manuscripts. This section describes basic mechanisms of intestinal 





Inflammatory bowel diseases, Crohn's disease, Ulcerative colitis, Fibrosis, Fistula, Genetic 
variants 
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Abbreviations 
 
5-ASA  5-aminosalicylic acid 
AZA  Azathioprine 
bFGF  Basic fibroblast growth factor 
CD  Crohn’s disease 
CXCR  Chemokine (CXC motif) receptor 
DAMP   Damage associated molecular pattern molecules 
DSS  Dextrane sodium sulfate 
ECM  Extracellular matrix 
EMT  Epithelial mesenchymal transformation 
FAK  Focal adhesion kinase 
FOX  Forkhead box 
FSP  Fibroblast specific protein 
HIF   Hypoxia inducible factors 
IBD  Inflammatory bowel disease 
ICAM  Intercellular adhesion molecule 1  
IFN  Interferon 
IFX  Infliximab 
IGF  Insulin-like growth factor 
IL  Interleukin 
IP  Interferon gamma-induced protein 
LFA-1  Lymphocyte function-associated antigen 1 
MAPK Mitogen activated protein kinase 
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MIF  Macrophage migration inhibiting factor 
MMP  Matrix metalloproteinase 
MUC  Mucin 
NFκB    Nuclear factor kappa-light-chain-enhancer of activated B cells  
NOD  Nucleotide-binding oligomerization domain containing 
NO  Nitric oxide 
PAMP  Pathogen associated molecular pattern molecules 
PI3K  Phosphoinositide-3 kinase 
SLPI   Secretory leucocyte protease inhibitor 
SMA  Smooth muscle actin 
SNP  Single nucleotide polymorphism 
SOD  Superoxide dismutase 
TAK  Transforming growth factor-β activated kinase 
TFF  Trefoil factors 
TGF  Transforming growth factor 
TIMP  Tissue inhibitor of matrix metalloproteinase 
TLR  Toll like receptor 
TNBS  Trinitro-benzene sulfonic acid 
TNF  Tumor necrosis factor 
UC  Ulcerative colitis 
VCAM Vascular cell adhesion molecule 1  
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The scientific committee of the European Crohn’s and Colitis Organization (ECCO) has 
launched a scientific workshop in 2010 on the relevance of intestinal healing for the disease 
course of inflammatory bowel disease (IBD). The overall objective of this workshop was to 
better understand and explore the importance of intestinal healing in IBD. The outcome of this 
workshop is presented in four separate publications: Mechanisms of intestinal healing (basic 
science), measures and markers to detect, achieve, and monitor intestinal healing, impact of 
intestinal healing on the course of IBD (natural history), and therapeutic strategies to enhance 
intestinal healing (therapy). This manuscript summarizes current knowledge about basic 
mechanisms of intestinal healing and discusses several key issues that need to be addressed in 
future studies. 
 
The achievement of mucosal healing is a critical endpoint in the treatment of patients with both 
ulcerative colitis (UC) and Crohn's disease (CD). Achievement of mucosal healing in patients 
with IBD carries the prospect of influencing the natural history of this disease by the prevention 
of complications, such as need for surgery or hospitalization rates. The understanding of basic 
mechanisms of wound generation and healing is crucial for the improvement of existing and 
development of future therapies. It is not only important to evaluate key mechanisms in mucosal 
injury but also to discuss early as well as late events in the intestinal wound healing response. 
Striking differences in wound healing between different IBD patients can be observed, which can 
be explained by differences in genetic or epigenetic factors, differences in the intestinal luminal 
components or distinct responses to drug therapies. 
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2. Definition of and players in intestinal wound generation in IBD 
 
2.1 Definition of mucosal injury 
 
The commonly used definition of mucosal injury generally refers to macroscopically visible 
mucosal lesions during endoscopy, and this definition will be used hereafter. However, this term, 
which is helpful for clinical purposes, should be distinguished from the immune-mechanistic 
concept of mucosal injury, as employed in the research arena. This immune-mechanistic 
definition is multi-layered and encompasses several strata: gap junction disruption at a molecular 
level, increased epithelial permeability at a sub-cellular level, epithelial apoptosis, infiltration of 
activated inflammatory and lymphocytic cells at the cellular level, villous and crypt architectural 
changes, granuloma formation and disruption of the muscularis layer at the microscopic tissue 
level, and finally – the creation of erosions and ulcers macroscopically visible by endoscopic 
examination.  
Moreover, in the current terminology, it is not universally agreed upon whether an isolated 
inflammatory process (for instance lamina propria inflammatory cell infiltration) qualifies for a 
mucosal injury or should this term be reserved for epithelial disruption only. Furthermore, it 
remains to be defined if mucosal healing should denote only a process restricted to the mucosa or 
should it include also the healing of sub-mucosa and muscularis layers as well as neuronal and 
lymphangiogenic elements of the intestinal wall. 
 
2.2 Key players in mucosal injury 
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Mucosal injury is likely initiated by a combination of endogenous and environmental factors. At 
first stage, it is believed that food-derived compounds, virus and bacterial-derived factors as well 
as host-derived factors may cause epithelial cell destruction leading to pathogen-associated 
molecular pattern molecule (PAMP) and damage associated molecular pattern molecule 
(DAMP)-dependent activation of innate and adaptive immunity. Damaged mucosa is initially 
infiltrated by diverse inflammatory cells consisting of neutrophils, eosinophils, mast cells, 
inflammatory monocytes, activated macrophages and dendritic cells. In parallel, specific adaptive 
immune responses towards the intestinal flora are generated leading to the later recruitment of 
activated B cells, CD4+ and CD8+ T cells to the inflamed mucosa.  
 
A number of molecules have been implicated in mediating the epithelial damage in IBD, leading 
to discernable mucosal lesions, but often their actual function and mechanism of action remains 
unclear. These molecules include, but are not restricted to:  
 
Tumor necrosis factor-α (ΤΝF):  TNF was shown to induce intestinal epithelial cell apoptosis (1, 
2), an effect that is abrogated by the ErbB4 growth factor receptor (3). However, it was also 
demonstrated that TNF exerts anti-apoptotic effects mediated by ErbB2 and epidermal growth 
factor (EGF) receptor (4), and that increased TNF levels correlate with inactive disease and lack 
of mucosal injury (5). Therefore, the exact role of TNF in instigating mucosal damage remains to 
be determined.  
 
Reactive oxygen and nitrogen species: These mostly include superoxide O2- and nitric oxide NO- 
which have been implicated in induction and propagation of epithelial mucosal injury (6). 
Increased levels of inducible nitric oxide (NO) synthase (iNOS) were found in IBD. iNOS 
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knock-out mice were protected against dextrane sodium sulfate (DSS) colitis (7) and experienced 
ameliorated trinitro-benzene sulfonic acid (TNBS) colitis when housed under SPF conditions (8). 
Notwithstanding, these iNOS knock-out animals paradoxically suffered from exaggerated colitis 
when induced by TNBS in non-specific pathogen free conditions (9) or when colitis was induced 
by the acetic acid model (10).   
Superoxide O2- has been similarly implicated in the etiogenesis of mucosal damage in IBD. High 
levels of the enzyme superoxide dismutase (SOD) that catalyses and eliminates O2- was 
documented in IBD mucosa (11). Lactobacillus expression of SOD ameliorated intestinal 
inflammation in interleukin (IL)-10 deficient mice (12) and in a rat TNBS colitis model (13). In 
contrast, SOD overexpressing mice, expected to have higher metabolic clearance of O2-, 
paradoxically exhibited more severe DSS-induced colitis compared to wild type mice (7). It 
remains unclear, if a certain threshold level of mucosal O2- is required for efficient clearance of 
invading bacteria. 
 
Matrix Metalloproteinases (MMP): Alterations in extracellular matrix (ECM) remodelling 
brought upon by an imbalance of certain MMPs and/or their inhibitors (in particular TIMP-1) 
have been implicated in inducing intestinal lesions in IBD. MMP-2, MMP-14, and TIMP-1 were 
increased significantly in the ulcerated mucosa of IBD patients but only slightly elevated in 
inflamed non-ulcerated section of intestine (14). Moreover, MMP-1,2,3 and 9 were increased in 
inflamed mucosa of IBD patients compared to the unaffected mucosa (14, 15). Inhibition of 
MMP activity was shown to ameliorate TNBS colitis (16). One possible mechanism for the 
preservation of mucosal integrity is action through substance P induced colonocyte proliferation 
(17). 
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Leptin:  Leptin was found to induce intestinal epithelial damage via activation of nuclear factor 
kappa-light-chain-enhancer of activated B cells (NFkB) (18). In contrast, NFkB activation (not 
by leptin) was essential for protection of intestinal epithelial cells from ischemia-induced 
apoptosis (2, 19) and probiotic-induced protection from colitis (20).  
 
Hypoxia inducible factor (HIF): HIF was found protective against TNBS colitis by enhancing 
barrier function and epithelial integrity (21, 22), but pro-inflammatory in DSS colitis by a 
macrophage migration inhibitory factor (MIF) dependent mechanism (23). These contradictory 
results were attributed to differences in the models used, namely the robust T-cell response in 
TNBS colitis as opposed to DSS, as well as to distinct effects of different HIF family members.  
 
While multiple molecules and complex mechanisms seem to be instrumental in initiation and 
propagation of mucosal injury, a fundamental question remains unresolved: Why do certain areas 
of the gut exhibit mucosal injury while others remain unaffected? In ulcerative colitis patients 
high levels of pro-inflammatory cytokines, such as interferon (IFN)-γ, TNF, IL-6, IL-15, IL-18, 
and IL-23, can be found in endoscopically affected and unaffected mucosa. Interestingly, 
mediators of direct mucosal injury (MMP-3, TIMP-1, iNOS, granzyme-B) were elevated only in 
the affected mucosa (24). In CD patients only Granzyme B was elevated in affected but not 
unaffected mucosa, whereas TIMP-1 and iNOS were upregulated independently of endoscopic 
involvement (24). In addition, cathepsins have been shown to contribute to mucosal damage (25, 
26). Thus, the differentiation between visibly ulcerated mucosa and normal appearing yet 
inflamed mucosa may be partly accounted for by the progression of the inflammatory process 
with up-regulation and/or expression of tissue damage mediators. It seems clear, however, that 
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there are other yet undefined mechanisms at play in dictating the progression to visible mucosal 
damage.  
 
2.3 Key messages and questions to address in the future 
 
Key messages 
• The endoscopic definition of mucosal injury needs to be separated from the immune 
mechanistic definition. 
• Mucosal injury is initiated by a multitude of endogenous and environmental factors and 
involves molecules, such as tumor necrosis factor, reactive oxygen species, matrix 
metalloproteinases, leptin, cathepsins and hypoxia inducible factor 
 
Questions to address in the future 
• We need to determine, which definition of mucosal injury or healing correlates best with the 
subsequent clinical course. Is it only the endoscopically visible lesion or would microscopic or 
even molecular perturbance of mucosal elements prove to be better predictors?  
• What are the specific food-derived compounds, virus and bacteria-derived factors and host-
derived or environmental danger signals inducing and perpetuating epithelial cell destruction?  
• What is the specific mode of action of the above named mediators in pathogenesis of mucosal 
injury and healing? 
• What triggers the progression from inflamed yet visually preserved mucosa to an inflamed 
overtly ulcerated mucosa and vice versa. 
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3. Early events in healing  
 
3.1 Definition of early intestinal healing 
 
The gastrointestinal mucosa provides a critical barrier, separating a myriad of environmental 
antigens within the intestinal lumen from the immune system of the host organism (27). Thus, 
early gastrointestinal wounding can be defined as a breakdown of the mucosal barrier function, 
leading to the translocation of antigens to the mucosal lamina propria, which is followed by the 
induction of acute and chronic inflammatory responses. Consequently, early mucosal wound 
healing can be described as the reestablishment of the intestinal mucosal barrier function. 
 
Within the complex context of early gastrointestinal wounding and wound healing, several 
mechanistic components can be separated. Rather than providing a comprehensive review that 
has been given elsewhere (28-30) we will concentrate our presentation on the contribution of the 
luminal mucus compartment, endogenous antimicrobial peptides, and the intestinal epithelial cell 
layer to the early events in intestinal wound healing. 
 
3.2 Gastrointestinal mucus layer 
 
For a long time it has been known that goblet cell depletion is a common phenomenon in IBD. 
Recent methodological advances allowed for the definition of sophisticated substructures within 
the gastrointestinal mucus layer (e.g. its phosphatidylcholine layer, lamellar bodies, mucin 
composition and glycosylation) (28, 31), which have been demonstrated to be of crucial 
importance for its barrier function (32-34).  The mucous layer and the bacteria residing in this 
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compartment form a protective ‘living wallpaper’ against exogenous bacteria through 
colonization resistance. Once the gastrointestinal mucus layer is disrupted, bacteria can penetrate 
the mucus and get in direct contact with epithelial cells, endangering mucosal homeostasis (35, 
36). It is however likely that not only early mucosal wounding but also wound healing starts at 
the level of the intestinal mucus layer. An intact mucus layer is critical to immediately fill the 
gaps in an injured epithelial layer, providing an initial ‘seal’ and thus preventing further damage 
(37, 38). Understanding the mechanisms how mucus is secreted, composed and modified and 
how these processes are altered in IBD, are therefore highly important for development of further 
therapeutic approaches (39). 
 
3.3 Paneth cells and defensins 
 
After disruption of the intestinal mucus and direct contact of the intestinal microbiota with the 
epithelial cell monolayer a second line of defense against bacterial invaders is of increasing 
importance: Paneth-cell- as well as enterocyte-derived defensins. Once secreted they become part 
of the intestinal mucus and their antimicrobial activity is crucial for the mucosal barrier function 
(40-42). Its disruption has been associated with the development of intestinal inflammation in 
mouse models as well as chronic IBD in humans (43-45). It is therefore likely that insufficient 
anti-bacterial activity in proximity to the epithelial cell monolayer leads to an impaired early 
wound healing response, and future efforts should target an early reestablishment of this 
compartment.  
 
3.4 Intestinal epithelial repair 
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Intestinal mucosal lesions in IBD, encompassing a numerous cells within the intestinal epithelial 
cell monolayer, necessitate a rapid resealing mechanism initiated by cells adjacent to the wound 
edges, which dedifferentiate (epithelial-mesenchymal transition, EMT), migrate over the wound 
to close the gap and re-differentiate including the formation of tight junctions (46). Smaller 
lesions allow a local purse-string mechanism via myosin light chain kinase activation in the 
epithelial cells surrounding the defect, rapidly closing the gap (47, 48). Host-derived factors 
support these healing mechanisms, e.g. growth factors and cytokines (49-52). Additionally, 
luminal factors (both host-derived and generated in the luminal environment) support intestinal 
epithelial wound healing, including intestinal trefoil factors (TFF, highly protease-resistant 
peptides secreted by goblet cells or their equivalents), bile acids, short chain fatty acids, adenine 
nucleotides, trace elements and the intestinal luminal microbiota themselves (52-57). 
 
On the molecular level, these mediators induce multiple signaling events within intestinal 
epithelial cells, including NF-κB-, mitogen activated protein kinase (MAPK)p38-, transforming 
growth factor (TGF)-β activated kinase (TAK)1-, focal adhesion kinase (FAK)-activation via 
Smad2/3 and protein kinase Akt-activation via phosphoinositide-3 kinase (PI3K) and via ErbB4. 
Downstream these signaling events exert mostly anti-apoptotic, pro-proliferative as well as pro-
migratory effects (3, 58-62). Remarkably, many of these signaling mechanisms can also be 
induced independently of external factors through simple mechanical wounding of an intestinal 
epithelial cell monolayer alone (63-66). However, the exact mechanisms leading to the activation 
of the various signaling pathways via mechanical wounding in enterocytes remain to be 
elucidated. 
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Of note, many of the signaling molecules activated during intestinal epithelial wound-healing 
play an important role during acute and chronic intestinal inflammation as well (67-70). As 
intestinal epithelial wound infliction and healing are almost invariably occurring in an 
inflammatory context, pro- and anti-inflammatory signaling pathways and molecular events 
during wound healing form a complex and mutually interactive network. Importantly, treatment 
regimens aimed at suppressing certain pro-inflammatory signaling have proven to be deleterious 
via suppression of wound healing responses, especially in the presence of intestinal damage (19, 
71). Further dissecting the intricate signaling network modulating intestinal epithelial cell 
proliferation, migration and apoptosis in gastrointestinal homeostasis and disease will be a 
prerequisite for the development of new therapeutic means aimed at these processes. 
 
Technically, it has proven challenging to imitate local intestinal epithelial wounding and wound 
healing in a controlled model system in vivo. Puncture wounds created by endoscopic techniques 
have been used (72), as has been mucosal ulcer generation via acetic acid saturated filter discs 
applied to the serosal side of the small bowel (60, 73). Recently, two-photon laser technology 
allowed the generation of wounds encompassing single intestinal epithelial cells (38). On the 
other hand, loss of epithelial cells is not a prerequisite of breaches of the intestinal epithelial 
barrier: Since the intestinal epithelial cell monolayer has to be selectively permeable to allow for 
nutrient, electrolyte and water absorption, its ‘sealing mechanism’ (namely tight junctions 
located apically between the enterocytes) is constantly replenished and modified. Thus, apart 
from macroscopically distinguishable breaches like for example the loss of epithelial cells, 
‘molecular breaches’ in tight junction permeability could be important in early wound generation 
(comprehensive review given in (30, 74)).  
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3.5 Key messages and questions to address in the future 
 
Key messages 
• Early intestinal healing can be defined as the re-establishment of the mucosal barrier 
function. 
• The gastrointestinal mucus layer is of critical importance for the repair and maintenance of 
the intestinal barrier function. 
• Disruption of endogenous antimicrobial activity is linked to intestinal injury and likely to an 
impaired wound healing response. 
• Molecules that induce intestinal epithelial restoration are also important in intestinal 
inflammation. 
 
Questions to address in the future 
• What is the molecular mucus composition and structure (e.g. role of glycosylation) and its 
differences in health versus IBD?  
• How is the secretion of phosphatidylcholine and antimicrobial effectors within the 
intestinal mucus layer regulated and stabilized? 
• What are the mechanisms behind the balanced and symbiotic relation of bacteria and its 
host in the intestinal mucus compartment? 
• What is the nature of intestinal ‘barrier breaches’: molecular (tight junction permeability) 
versus macroscopic? Which pathways or cell types are responsible for sensing a breach in the 
intestinal barrier: NF-κB, MAPKp38, intestinal epithelial cells, dendritic cells?  
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• How do injury and inflammation intersect to rapidly induce wound healing mechanisms 
following an intestinal ‘barrier breach’ (mucus production, enterocyte proliferation, migration, 
apoptosis and cytokine secretion)? 
• We need to further refine the technical means to investigate early gastrointestinal 
wounding/wound healing in vivo to enable more detailed investigations (e.g. two-photon-
microscopy, lipidomics, proteomics and endoscopic techniques being the most promising 
approaches to date). 
 
 
4. Late events in healing  
 
4.1 Chronic wound repair and disease complications 
 
In contrast to the intensive investigation of the immunological mechanisms of the early phases of 
intestinal inflammation and repair, the pathophysiology of chronic mucosal wound healing and 
the late events of repair remain largely unexplored. This is unfortunate, because insufficient 
(abscess, fistula) or excessive wound healing (fibrostenosis) are the main indications for surgery 
in patients with CD (75, 76). However, this process does not seem to happen in all patients, as up 
to one quarter of patients with CD continue to have a purely inflammatory phenotype, even after 
25 years of disease (77). In patients with UC, chronic wound healing can induce fibrotic changes, 
including structural changes (haustral loss, colonic shortening), and disordered motility. These 
findings make it likely that intestinal inflammation is an important initiating event, which can 
either be followed by normal restitution, or by pathologic fibrosis and/or fistula formation (76, 
78). It remains unclear, which signals and pathways initiate chronic wound healing abnormalities 
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in late healing, rather than normal restitution and resolution. If normal restitution and pathologic 
healing after inflammation are distinct pathways, these could be separately targeted, allowing 
selective therapy for the wound healing abnormalities seen in IBD. 
 
4.2 Extracellular matrix as a driver of inflammation and wound repair 
 
It is apparent from study of other organs that undergo fibrosis (e.g. lung, liver, and kidney), that 
once fibrosis is established it becomes an independent and self-perpetuating process, without a 
necessity for ongoing inflammation to drive matrix deposition (79). This could be true for fibrotic 
and stricturing CD as well. Possible mechanisms include [1] the intestinal ECM acting as a 
binding partner or reservoir for pro-fibrotic tissue factors (80), [2] the increased stiffness of the 
tissue acting as a stimulus for mechanosensitive cells to deposit and crosslink additional 
extracellular matrix in case of stricture formation, [3] reduced ECM stiffness leading to reduced 
matrix deposition in the case of fistulae (81). ECM is not an inactive structure, but directly 
regulates the inflammatory response and the process of healing and fibrosis by focal adhesions 
with immune and non-immune cells, such as myofibroblasts (82).  
 
4.3 Sources of myofibroblasts and mechanisms of their activation 
 
Activated myofibroblasts, a key effector cell type in intestinal wound healing, can be derived not 
only from resident mesenchymal cells, but also from other cell populations, including epithelial 
and endothelial cells (by a process termed epithelial-/endothelial- mesenchymal transition), 
stellate cells, pericytes, local stem cells and bone-marrow-derived cells (fibrocytes) (79, 83, 84). 
However, almost nothing is known about the functional relevance, mechanisms and targets for 
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intervention. A multitude of molecules derived from essentially all cell types involved in IBD can 
activate myofibroblasts. In addition, microbial PAMPs or DAMPs, critical for sterile 
inflammation, could be involved (85, 86).  
 
The field of intestinal mesenchymal cells lacks critical technical tools: We need to define specific 
markers for myofibroblasts, a cell type most critically involved in wound healing and restitution. 
Specific subsets of mesenchymal cells may be identified that are particularly important in wound 
repair. Thus far no promoter specific for intestinal mesenchymal cells/myofibroblasts, useful for 
the generation of cell type specific transgenic mice, has been identified. Markers, such as 
fibroblast specific protein (FSP)-1 and α-smooth muscle actin (SMA) can be helpful, but are also 
expressed in additional cell types in intestinal fibrosis other than fibroblasts/myofibroblasts.  
 
4.4 Regulation of extracellular matrix turnover 
 
The fine balance between MMPs and TIMPs appears to be disturbed in chronically impaired 
wound healing in IBD (14). It is unclear which specific MMPs and TIMPs are involved and how 
they are regulated in this process. Our current understanding of intestinal fibrosis assumes that the 
amount of accumulated fibrotic tissue damage is linked to the likelihood of formation of fistulae 
or strictures. Effective pharmacological modulation of the MMP/TIMP-system could be helpful in 
the reversal of accumulated tissue fibrosis or healing of already formed fistulae (87). 
  
Limited animal models for intestinal fibrosis exist, though several new models have recently 
been introduced. Virtually no animal model exists that helps our understanding of fistula 
formation. The field is in need of additional factors/molecules able to modulate the wound 
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healing response, which may include microRNAs. Delivery systems designed to direct these 
molecules to the deep layers of the human intestine need to be developed to allow broad 
application in clinical studies. Ultimately, non-invasive means to monitor and measure intestinal 
fibrosis and fistula formation in animals and humans are critical to provide endpoints for 
developing and testing specific anti-fibrotic therapies. 
 
4.5 Key messages and questions to address in the future 
 
Key messages 
• Chronic intestinal wound healing abnormalities can lead to complications, such as 
formation of strictures or fistulae. 
• The extracellular matrix is an active player in intestinal inflammation and repair. 
• Intestinal myofibroblasts are derived from a multitude of sources and can be activated by 
classical pro-inflammatory signals and growth factors but also by environmental and bacterial 
components. 
• In chronically impaired wound healing a disturbance of the MMP/TIMP balance can be 
observed. 
 
Questions to be addressed in the future 
• Which factors determine the switch from a purely inflammatory disease course to a 
complicated disease course? Do these factors appear early or late in the disease process? What are 
the differences between early and late disease? 
• Is there a ‘point of no return’ in stricture and fistula formation? 
• What are the mechanisms of auto-propagation of intestinal fibrosis and fistula formation? 
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• How does the matrix itself actively contribute to the abnormalities in wound healing? 
• What is the main source of myofibroblasts in intestinal wound healing? 
• What are the specific molecular markers of myofibroblasts?  
• What are the main mediators of myofibroblast activation? What is their functional 
relevance, what are the mechanisms and targets for intervention? 
• What is the role of the environment in activation of intestinal mesenchymal cells (possibly 
mediated through PAMPs and DAMPs)? 
• What are the sources of MMPs and TIMPs in intestinal inflammation? Does an imbalance 
of this system early in the disease cause later complications? Can MMPs and TIMPs be used for 
the therapy of existing fistulae and strictures? 
 
 
5. Determinants of intestinal healing 
 
The ability to regenerate the intestinal mucosa greatly varies among different IBD patients, as 
well as, in a given patient, over time. Such heterogeneity implies the existence of certain factors 
influencing the molecular mechanisms responsible for mucosal healing. On one hand, genetic 
factors, including both the genetic background of the patient and post-transcriptional and 
epigenetic modifications could influence mucosal healing. On the other hand, acquired, 
environmental or “luminal” factors, such as the bowel microbiota, its products, diet components 
or even drugs might also play a key role in that process.  
 
5.1 Genetic variants in IBD  
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Influence of genetic factors on IBD susceptibility and phenotype: According to our present 
understanding, both CD and UC develop in genetically susceptible subjects. The fact that genetic 
factors play a key role in the development of IBD is beyond any doubt. Many lines of evidence, 
including a higher risk in first-degree relatives, studies in monozygotic and dizygotic twins, 
greater prevalence in certain ethnic groups, identification of specific disease susceptibility genes 
and even results from animal models point towards a key role of genetic factors in IBD. 
Similarly, the fact that both CD and UC are polygenic conditions is undisputed. Two recent 
collaborative studies of the International Consortium for the Study of IBD genetics (88, 89) have 
identified 71 single nucleotide polymorphisms (SNPs) independently associated with a higher 
risk to develop CD (88) and 47 SNPs predisposing to UC (89). A very interesting concept 
emerging from these studies is the fact that some SNPs are common to both entities, suggesting 
that these factors facilitate “intestinal inflammation” in general, whereas other SNPs only 
increase the risk of developing either CD or UC, which means that these genetic factors are 
“more specific”, influencing only a certain type of intestinal inflammation. 
 
Compared to our quite comprehensive understanding of the genetic factors determining CD and 
UC susceptibility, much less is know about the influence of genetic factors on disease phenotype, 
development of IBD-related complications and response to IBD therapies. The currently 
strongest disease-modifying gene seems to be nucleotide-binding oligomerization domain 
containing (NOD)2. Their three main variants have been associated to increased ileal disease 
location, stenosing phenotype and risk of surgery (90, 91). 
 
Influence of genetic factors on intestinal healing in IBD patients: Unfortunately, there are no 
studies specifically aimed at identifying which genetic factors are independently associated with 
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a better or worse mucosal healing response in IBD patients. In spite of this obvious limitation, we 
can speculate that the genetic factors influencing, on one hand, the development of intestinal 
inflammation and injury and, on the other hand, the mechanisms of wound healing and repair 
might play a relevant role. In the first group a large number of genes, encoding the expression of 
molecules critical in inflammation and innate immunity, such as the NOD, TLR, and TNF 
families might constitute good candidate genes to influence mucosal healing. In the second gene 
group, and among the molecules responsible to regulate the wide spectrum spanning from 
physiological wound healing to abnormal fibrogenesis, several metalloproteinases and their 
inhibitors, as well as other key regulatory molecules, such as TGF-β, basic fibroblast growth 
factor (bFGF), and insulin-like growth factor (IGF)-1, would be excellent candidates. 
 
To date most efforts in the field of IBD genetics have been devoted to the identification DNA-
related genetic factors (single nucleotide polymorphisms). However, the potential relevance of 
other types of genetic factors, such as copy number variants, the degree of gene expression 
(mRNA), the existence of inhibitory RNA sequences (microRNAs), as well as the influence of 
DNA methylation and other epigenetic changes has been recently recognized and seems likely to 
be able to account for part of the observed variation in the process of mucosal healing in IBD 
patients. An excellent example is the study recently published by Arijs et al (92): Gene 
expression was assessed at both blood and tissue levels and the authors were able to identify a 
mucosal gene signature consisting of a combination of 5 expressed genes. This model showed a 
high accuracy in predicting response to infliximab in UC patients, as determined by endoscopic 
and histological remission (92). 
 
5.2 Impact of butyrate on intestinal healing 
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As stated above the intestinal luminal compartment, such as mucus, endogenous anti-microbial 
factors and the epithelial barrier are critical in early wound generation and healing in the 
intestine. In addition to this an innumerous variety of compounds is present in the free lumen of 
our intestines.  
 
A major fraction of these luminal factors, with reported impact on intestinal healing and the 
symbiotic host-to-microorganism relationship are derived directly or indirectly from bacteria. 
This occurs via affecting a multitude of immune and non-immune cells of the lamina propria at 
any time during development and activation of the human immune system (30). One of the best-
characterized bacterial products known to have beneficial effects on the intestinal healing 
response is butyrate. Butyrate arises during the fermentation of starch by members of the 
anaerobe Clostridium subphylum species, i.e. clusters IV (Faecalibacterium prausnitzii, 
Butyricicoccus pullicaecorum) and XIVa (Butyrivirio fibrisolvens) (93). Interestingly, both the 
depletion of these members and the occurrence of antibodies directed against their flagellins are 
linked to IBD (94).  As no comprehensive overview on all bacterial factors involved can possibly 
be presented, butyrate will serve as our example for luminal factors determining intestinal wound 
healing. The anti-inflammatory effect of butyrate has been shown in various in vitro and in vivo 
systems providing a rationale for assessing its therapeutic potential (95-97).  Butyrate can affect 
early and late events in intestinal healing. 
 
In vitro stimulation of intestinal biopsies with butyrate increased mucus synthesis (98). In a 
human colonic goblet cell line stimulation with butyrate from the apical side of the cells led to an 
increase in the expression of MUC2, MUC3 and MUC5B the genes encoding mucins (99). Very 
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limited information is available concerning the effects of butyrate on the expression of 
antimicrobial peptides. Treatment of colon epithelial cell lines with butyrate induces upregulation 
of human cathelicidin (LL-37) mRNA expression (100), a lysosomal antibacterial peptide. This 
is mediated by recruitment of PU.1 to the cathelicidin antimicrobial peptide promoter, the gene 
encoding LL-37. Butyrate exhibits a well-established role as a major energy source for 
enterocytes, but is also able to stimulate genes that are important for epithelial integrity, e.g. by 
affecting histone acetylation and DNA methylation. Butyrate facilitates tight junction assembly 
(101) and reduces metabolic stress induced loss of epithelial integrity – a mechanism that led to 
protection from enhanced bacterial translocation (102). 
 
Butyrate has been shown to reduce the inflammatory cytokine driven production of MMP-1 and 
MMP-3 in colonic myofibroblasts (103). Interestingly, butyrate also reduced the expression of 
cytokine-induced IFN-gamma-induced protein (IP-10) by intestinal myofibroblasts, a factor 
reported to mediate chronic inflammation by recruiting T-cells and monocytes (104). To the 
contrary, butyrate was shown to enhance cytokine-induced stromelysin-1 expression thereby 
contributing to the inflammatory response (105). More knowledge about functional consequence 
of exposure of myofibroblasts to butyrate is needed. 
 
These diverse actions of butyrate on different phases of intestinal wound healing makes it likely 
that additional luminal factors like bacteria themselves or their released products have a 
considerable role in this process. These factors need to be explored with the prospect as potential 
future therapeutics. 
 
5.3 Molecular action of drugs on intestinal healing 
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While exploration of the role of genetic, epigenetic or luminal components to wound healing is 
critical for the development of future therapeutic approaches it is also prudent to thoroughly 
understand the molecular actions of our current IBD drug repertoire. This can help optimize 
existing treatment protocols by enhancing their efficacy and reducing their side effects. 
 
Compounds, administered through any route, can signal at different levels of the intestinal 
mucosa (106): Pre-epithelial (intestinal mucus, bacteria), epithelial, post-epithelial (mucosal 
immune and non-immune compartments, modulation of cytokines and growth factors) or in a 
fashion combining all the above. Although ample data is available on clinical outcomes of IBD 
therapy, information regarding mechanisms of action are scarce. 
 
5-aminosalicylic acid/sulfasalazine: Treatment with 5-aminosalicylic acid (5-ASA) has been 
associated with an abrogation of NFκB activation in situ (107), which went along with reversal 
of microscopic alterations in the IBD mucosa like the mixed inflammatory infiltrate in the lamina 
propria, crypt architectural abnormalities, basally located lymphoid aggregates, basal 
plasmacytosis, villiform surface epithelial configuration and Paneth cell metaplasia (108). 5-ASA 
lowered IL-1β and leukotriene B4 release from cultured biopsy specimens from the inflamed 
colonic mucosa of patients with active inflammatory bowel disease (109). In vitro models show 
that sulfasalazine exerted a direct effect on intestinal lamina propria leukocytes and peripheral 
blood leukocytes of IBD patients and healthy subjects, by triggering a potent pro-apoptotic 
effect, an action that stood in contrast to 5-ASA (110). Mesalazine is affecting cell migration and 
proliferation of intestinal epithelial cell lines, two key processes in mucosal healing, an effect 
dependent on TGF-β (111). The combination of N-acetylcysteine plus 5-ASA induced mucosal 
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healing by suppressing cyclooxigenase-2 gene expression and prostaglandin E2 levels in a TNBS 
rat colitis model (112). 
 
Corticosteroids: Corticosteroid-induced healing of colonic inflammation is associated with a 
reduction of NFkB in nuclear extracts derived from intestinal mucosal biopsies of IBD patients 
(113). Dexamethasone lowered the release of IL-1β and leukotriene B4 from IBD derived 
mucosal biopsies (109). High concentrations of prednisolone and budesonide, in contrast to 
lower concentrations, had inhibitory effects on proliferation and restitution of intestinal epithelial 
cells (114). These results were partially confirmed by other groups, that showed a steroid-
induced inhibition of intestinal epithelial cell migration and proliferation (115). Dexamethasone 
suppressed growth factor induced epithelial restitution by inhibiting prostaglandins using two 
cultured cell wound-resealing models (116). 
 
Azathioprine and Cyclosporine A: Azathioprine (AZA)-driven mucosal healing was associated 
with a decrease of the inflammatory infiltrate in the ileal mucosa from CD patients (117). AZA 
profoundly inhibits intestinal epithelial cell growth by causing a G2 cell cycle arrest, inducing 
apoptosis and dose-dependently inhibiting proliferation (118). The frequency of intestinal 
mucosal TNF secreting cells is reduced in pediatric CD patients upon treatment with cyclosporin 
A but not with corticosteroids or enteral nutrition treatment, although no clear relation existed 
between histological healing and the frequency of TNF secreting cells (119).  
 
Infliximab: IBD patients receiving the anti-TNF antibody infliximab (IFX) showed an 
improvement in their increased intestinal permeability (120). Treatment leads to lower global 
numbers of CD4+ and CD8+ T lymphocytes and monocytes (121) and of mucosal CD68, a 
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marker for monocytes/macrophages (122). IFX down-regulated mucosal expression of forkhead 
box (Fox)p3, a marker for T-regulatory cells, while increasing their circulating levels (123). The 
mucosal expression of gelatinase B and TNF is reduced and this effect that was linked to 
endoscopic and/or histologic improvement (122). IFX lowers the expression of the cell 
recruitment molecules intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion 
molecule-1 (VCAM-1) and lymphocyte function-associated antigen 1-(LFA-1). In vitro studies 
have shown that infliximab reduces the T-cell secretion of IFN-γ, likely because its synthesis is 
dependent on TNF levels. (124, 125). IFX attenuated intestinal mucosal MMP-3 and -12 
synthesis but elevated the expression of antimicrobial peptides (121, 126-128). Finally, 
infliximab treatment was associated with improvement in morphology and function of the 
epithelial organelles, mucus secretion and recovery of the chorionic components at transmission 
electron microscope analysis (129).  
 
Probiotics: Probiotics can induce regulatory cytokines, including IL-10 and TGF-β, and suppress 
TNF, in the mucosa of patients with CD and pouchitis (130). VSL#3, a probiotic mixture of 8 
lactic acid bacteria probiotic strains or E. coli Nissle 1917, induces IL-10 and downregulates IL-
12p40 production by lamina propria dendritic cells in patients with UC, changes similar to 
patients who were treated with corticosteroids (130, 131). VSL#3 has been linked to the 
enhancement of the increased expression of costimulatory molecules like CD80 (B7-1), CD86 
(B7-2) and CD40, and of MHC class II in dendritic cells (131). E coli Nissle 1917 ameliorated 
DSS-colitis, an effect likely mediated by toll like receptor (TLR)-2 and TLR-4 (132). The 
probiotic bacterium bacillus polyfermenticus has been shown to increase angiogenic properties of 
human intestinal microvascular endothelial cells in a NF-kappaB/IL-8/chemokine (CXC motif) 
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receptor (CXCR)2-dependent manner, suggesting that it may be clinically used to facilitate 
intestinal wound healing (133). 
 
Antibiotics: Even though metronidazole and ciprofloxacin are the most commonly used 
antibiotics in IBD many studies were performed on rifaximin, a non-absorbable derivative of 
rifamycin. In the TNBS-colitis model rifaximin reduced colitis severity and decreased the levels 
of several pro-inflammatory cytokines (134). Ciprofloxacin inhibits the cytokine-induced iNOS 
mRNA expression in HT-29 cells and a similar inhibitory effect was detected in vitro in cultures 
of normal colonic tissue and in cultures of colonic tissue from ulcerative colitis patients (135).  
 
5.4 Key messages and questions to address in the future 
 
Key messages 
• The link between genetic variants and susceptibility to IBD has been well established. 
However information on the influence of genetic factors on intestinal healing is lacking. 
• Luminal factors, directly or indirectly derived from bacteria, have an impact on intestinal 
healing and could account for the variability in the wound healing response. 
• The mechanisms of action of our current IBD drug repertoire are under investigation, but still 
poorly understood. 
 
Questions to address in the future 
• What is the influence of different genetic and epigenetic factors (SNPs, copy number 
variants, mRNA gene expression, microRNA expression) - alone or in combination - on mucosal 
healing? 
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• Trials with the primary outcome of intestinal healing need to be designed. 
• Are local epigenetic changes involved in the focal and segmental nature of fibrosis and 
fistula formation? 
• What are the key components of the luminal compartment that trigger intestinal 
inflammation and repair? 
• How can the observed alterations in the luminal compartment during intestinal 
inflammation (e.g. butyrate) be used to guide us to novel therapeutic approaches? 
• We need to develop cell or compartment specific drug delivery systems 
• How do the currently available IBD therapeutics influence the late healing response and 
how do they affect the occurrence of complications on a molecular level? 
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